{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:35:53Z","timestamp":1793144153921,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inflammatory bowel disease (IBD) is characterized by intestinal inflammation; however, it is also known to have extraintestinal manifestations. Ocular manifestations of IBD include keratopathy, episcleritis, scleritis, and uveitis and are among the most common extraintestinal manifestations. These diseases can lead to significant ocular morbidity if unrecognized and left untreated. A review of the literature was performed on PubMed and is summarized and critically appraised in this article with the aim being to describe the varying ocular manifestations of IBD and outlining their treatments. Ultimately, a framework is provided to investigate ocular symptoms in patients with IBD. An ocular review of systems is also provided as a tool to equip gastroenterologists and internal medicine physicians to be able to recognize and triage ocular complaints appropriately.<\/jats:p>","DOI":"10.1093\/ibd\/izaa359","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T13:11:50Z","timestamp":1611753110000},"page":"1832-1838","source":"Crossref","is-referenced-by-count":39,"title":["Ocular Manifestations of Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"27","author":[{"given":"Janaki","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Washington University in St. Louis , St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaditya","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Washington University in St. Louis , St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Hassman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Washington University in St. Louis , St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Washington University in St. Louis , St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"2022092120051681300_CIT0001","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0002","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.3748\/wjg.v11.i46.7227","article-title":"Extraintestinal manifestations in inflammatory bowel disease","volume":"11","author":"Danese","year":"2005","journal-title":"World J Gastroenterol."},{"key":"2022092120051681300_CIT0003","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol."},{"key":"2022092120051681300_CIT0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"31","author":"Su","year":"2002","journal-title":"Gastroenterol Clin North Am."},{"key":"2022092120051681300_CIT0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol."},{"key":"2022092120051681300_CIT0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","article-title":"Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease","volume":"10","author":"Karmiris","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092120051681300_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1026629528233","article-title":"Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis","volume":"44","author":"Das","year":"1999","journal-title":"Dig Dis Sci."},{"key":"2022092120051681300_CIT0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00054725-199805000-00026","article-title":"Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD","volume":"4","author":"Salmi","year":"1998","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0009","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/gast.2002.35396","article-title":"Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes","volume":"123","author":"Orchard","year":"2002","journal-title":"Gastroenterology."},{"key":"2022092120051681300_CIT0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0016-5085(00)70209-5","article-title":"Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease","volume":"118","author":"Orchard","year":"2000","journal-title":"Gastroenterology."},{"key":"2022092120051681300_CIT0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2022092120051681300_CIT0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0016-5085(94)90066-3","article-title":"A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody","volume":"107","author":"Bhagat","year":"1994","journal-title":"Gastroenterology."},{"key":"2022092120051681300_CIT0013","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0016-5085(90)90839-S","article-title":"A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody","volume":"98","author":"Das","year":"1990","journal-title":"Gastroenterology."},{"key":"2022092120051681300_CIT0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092120051681300_CIT0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/00365521.2014.991752","article-title":"Extraintestinal manifestations in Crohn\u2019s disease and ulcerative colitis: results from a prospective, population-based European inception cohort","volume":"50","author":"Isene","year":"2015","journal-title":"Scand J Gastroenterol."},{"key":"2022092120051681300_CIT0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ibd.20584","article-title":"Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study","volume":"15","author":"Felekis","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0017","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00384-007-0275-1","article-title":"The prevalence of ocular involvement in patients with inflammatory bowel disease","volume":"22","author":"Yilmaz","year":"2007","journal-title":"Int J Colorectal Dis."},{"key":"2022092120051681300_CIT0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10067-007-0797-5","article-title":"A cross-sectional study of 130 Brazilian patients with Crohn\u2019s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations","volume":"27","author":"Lanna","year":"2008","journal-title":"Clin Rheumatol."},{"key":"2022092120051681300_CIT0019","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients","volume":"20","author":"Zippi","year":"2014","journal-title":"World J Gastroenterol."},{"key":"2022092120051681300_CIT0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8518-3","article-title":"Ocular involvement in systemic autoimmune diseases","volume":"49","author":"Generali","year":"2015","journal-title":"Clin Rev Allergy Immunol."},{"key":"2022092120051681300_CIT0021","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5217\/ir.2017.15.3.380","article-title":"Ophthalmologic manifestations in patients with inflammatory bowel disease","volume":"15","author":"Lee","year":"2017","journal-title":"Intest Res."},{"key":"2022092120051681300_CIT0022","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-9394(14)75202-X","article-title":"The keratopathy of Crohn\u2019s disease","volume":"90","author":"Knox","year":"1980","journal-title":"Am J Ophthalmol."},{"key":"2022092120051681300_CIT0023","doi-asserted-by":"crossref","first-page":"S420","DOI":"10.1097\/ICL.0000000000000537","article-title":"Conjunctival impression cytology and tear-film changes in patients with inflammatory bowel disease","volume":"44","author":"Do\u011fan","year":"2018","journal-title":"Eye Contact Lens."},{"key":"2022092120051681300_CIT0024","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ibd.21180","article-title":"Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease","volume":"16","author":"Cury","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0025","first-page":"109","article-title":"Peripheral corneal infiltrates in inflammatory bowel disease","volume":"13","author":"Schulman","year":"1981","journal-title":"Ann Ophthalmol."},{"key":"2022092120051681300_CIT0026","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v9.i10.2300","article-title":"Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study","volume":"9","author":"Lakatos","year":"2003","journal-title":"World J Gastroenterol."},{"key":"2022092120051681300_CIT0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12664-015-0598-8","article-title":"Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients","volume":"34","author":"Bandyopadhyay","year":"2015","journal-title":"Indian J Gastroenterol."},{"key":"2022092120051681300_CIT0028","doi-asserted-by":"crossref","first-page":"438402","DOI":"10.1155\/2015\/438402","article-title":"Ocular complications of inflammatory bowel disease","volume":"2015","author":"Mady","year":"2015","journal-title":"Scientificworldjournal."},{"key":"2022092120051681300_CIT0029","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJM200008033430507","article-title":"The red eye","volume":"343","author":"Leibowitz","year":"2000","journal-title":"N Engl J Med."},{"key":"2022092120051681300_CIT0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0161-6420(91)32268-1","article-title":"Ocular inflammation in Crohn\u2019s disease","volume":"98","author":"Salmon","year":"1991","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0031","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.eye.6701632","article-title":"A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis","volume":"19","author":"Williams","year":"2005","journal-title":"Eye (Lond)."},{"key":"2022092120051681300_CIT0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-200403000-00012","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"10","author":"Mintz","year":"2004","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00347-016-0344-3","article-title":"Diagnosis and treatment of episcleritis and scleritis","volume":"113","author":"Tappeiner","year":"2016","journal-title":"Ophthalmologe."},{"key":"2022092120051681300_CIT0034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","article-title":"Clinical characteristics of a large cohort of patients with scleritis and episcleritis","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0002-9394(14)77013-8","article-title":"Crohn\u2019s disease and retinal vascular disease","volume":"110","author":"Ruby","year":"1990","journal-title":"Am J Ophthalmol."},{"key":"2022092120051681300_CIT0036","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/pgmj.71.833.170","article-title":"Retinal vasculitis associated with Crohn\u2019s disease","volume":"71","author":"Garcia-Diaz","year":"1995","journal-title":"Postgrad Med J."},{"key":"2022092120051681300_CIT0037","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch Ophthalmol."},{"key":"2022092120051681300_CIT0039","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol."},{"key":"2022092120051681300_CIT0040","doi-asserted-by":"crossref","first-page":"1756284819865142","DOI":"10.1177\/1756284819865142","article-title":"Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study","volume":"12","author":"Biedermann","year":"2019","journal-title":"Therap Adv Gastroenterol."},{"key":"2022092120051681300_CIT0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","article-title":"Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits","volume":"10","author":"Taleban","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092120051681300_CIT0042","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/ICU.0000000000000310","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"27","author":"Thomas","year":"2016","journal-title":"Curr Opin Ophthalmol."},{"key":"2022092120051681300_CIT0043","article-title":"Long-term efficacy and tolerability of TNFalpha inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study","author":"Sharma","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"2022092120051681300_CIT0044","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CP202171","article-title":"Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults","volume":"53","author":"Borr\u00e1s-Blasco","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"2022092120051681300_CIT0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/09273948.2016.1236968","article-title":"Efficacy of anti-TNF-\u03b1 therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients","volume":"26","author":"Mercier","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"2022092120051681300_CIT0046","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol."},{"key":"2022092120051681300_CIT0047","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S0002-9270(02)04930-4","article-title":"Treatment of acute episcleritis associated with Crohn\u2019s disease with infliximab","volume":"97","author":"Finkelstein","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"2022092120051681300_CIT0048","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ophtha.2018.05.014","article-title":"Targeting interleukin-23 in the treatment of noninfectious uveitis","volume":"125","author":"Pepple","year":"2018","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0049","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn\u2019s disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022092120051681300_CIT0050","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2022092120051681300_CIT0051","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep."},{"key":"2022092120051681300_CIT0052","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092120051681300_CIT0053","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","article-title":"Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study","volume":"122","author":"Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group","year":"2015","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0054","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0055","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.ajoc.2020.100633","article-title":"Certolizumab pegol\u2014tumor necrosis factor inhibitor for refractory uveitis","volume":"18","author":"Sharon","year":"2020","journal-title":"Am J Ophthalmol Case Rep."},{"key":"2022092120051681300_CIT0056","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"2022092120051681300_CIT0057","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2022092120051681300_CIT0058","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol."},{"key":"2022092120051681300_CIT0059","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Ka\u00e7maz","year":"2010","journal-title":"Ophthalmology."},{"key":"2022092120051681300_CIT0061","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: the limitations of corticosteroid therapy in Crohn\u2019s disease","volume":"15","author":"Rutgeerts","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092120051681300_CIT0062","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12886-015-0047-6","article-title":"Systemic adalimumab induces peripheral corneal infiltrates: a case report","volume":"15","author":"Matet","year":"2015","journal-title":"BMC Ophthalmol."},{"key":"2022092120051681300_CIT0063","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflamm Infect."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/11\/1832\/45954131\/izaa359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/11\/1832\/45954131\/izaa359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T20:06:32Z","timestamp":1663790792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/11\/1832\/6121235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa359","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,1,27]]}}}